

# Clinical Utility of the 12-gene Ductal Carcinoma in situ (DCIS) Score: Impact on Treatment Recommendations

Leonard CE,<sup>1</sup> Lei RY,<sup>1,2</sup> Alvarado M,<sup>3</sup> Guenther JM,<sup>4</sup> Hagans J,<sup>5</sup> Manders J,<sup>6</sup> Schultz MJ,<sup>7</sup> Sing AP,<sup>8</sup> Broder MS,<sup>9</sup> Chang E,<sup>9</sup> Cherepanov D,<sup>9</sup> Hsiao W,<sup>10</sup> Carter D<sup>2</sup> On behalf of the patients participating in the study

<sup>1</sup>Rocky Mountain Cancer Centers, Littleton, CO; <sup>2</sup>Rocky Mountain Cancer Centers, Aurora, CO; <sup>3</sup>University of California, San Francisco, CA; <sup>4</sup>St. Elizabeth Healthcare, Edgewood, KY; <sup>5</sup>The Surgical Clinic of Central Arkansas, Little Rock, AR; <sup>6</sup>The Christ Hospital, Cincinnati, OH; <sup>7</sup>University of Maryland St. Joseph Medical Center, Towson, MD; <sup>8</sup>Genomic Health, Inc., Redwood City, CA; <sup>9</sup>Partnership for Health Analytic Research, LLC, Beverly Hills, CA; <sup>10</sup>University of Southern California, Los Angeles, CA;

## BACKGROUND

- The incidence of ductal carcinoma *in situ* has dramatically increased over the past 30 years with the advent of routine mammography starting at age 40 years for most women.<sup>1</sup>
- The rate of invasive disease and breast cancer related death, however, has been relatively stable and has not increased in incidence over the same time period.<sup>1</sup>
- DCIS now accounts for approximately 20% of all breast cancers in the US.<sup>2</sup>
- Local recurrence (LR) rates with surgery alone range from 15–60%; about 50% of local recurrences are invasive.<sup>3</sup>
- Radiation therapy (XRT) reduces LR by 50% but has not been shown to impact overall or disease-free survival.<sup>4</sup>
  - No studies have been able to identify a patient group that did not derive benefit (ie risk reduction) with XRT.
- Clinicians and patients must decide between multiple treatment options, including breast conserving surgery, mastectomy, partial or whole breast XRT, and hormonal manipulation.<sup>2</sup>
- The decision around recommending XRT is dependent on an assessment of LR risk with an assumption that around half of those recurrences will be invasive disease.
- Additionally, while reduction of LR, particularly invasive LR, is important, there are other goals of therapy that are taken into consideration, such as cosmetic outcomes and side effects from XRT.
- Currently, LR risk is estimated based on clinicopathologic factors and provides an average risk derived from population studies.
  - For example, younger patients or patients with higher grade DCIS are considered higher risk and are generally treated more aggressively.
- The 12-gene assay for DCIS (Oncotype DX<sup>®</sup>) is the first molecular assay that gives additional independent and individualized estimates of 10-year risk of any LR and invasive LR.<sup>5</sup>
- The result (DCIS Score<sup>™</sup>) was clinically validated in a cohort of patients from the ECOG 5194 study who were selected for observation (no XRT) after surgical excision based on characteristics conferring a low risk of LR.
- The DCIS Score results showed that in this group of patients, there was a range of scores and patients who could be categorized at low, intermediate, or high risk of LR based on the biology of the disease as measured by the expression of 12 of the 21 genes in the Oncotype DX invasive breast cancer assay (7 cancer related genes and 5 reference genes).<sup>5</sup>
- While age and size were prognostic, other measures (including grade, comedo necrosis, and margin width) were poor predictors of LR. There was a range of DCIS Score results across any of the measures, indicating that these measures were unable to “predict” what the score result would be.
- In addition, the DCIS Score result was significantly associated with the risk of an invasive LR, separate from the overall LR risk.

## RESULTS

### Patients

- 122 patients were enrolled at 10 centers (RMCC 5 sites) throughout the US from September 2012 to February 2014
- 115 patients were evaluable for the primary analysis. Excluded patients: no DCIS Score result (N=4), mastectomy planned (N=1), declined Oncotype DX testing (N=1), no DCIS on final pathology (N=1)
- The evaluable patients were enrolled by 5 radiation oncologists (48 patients; 41.7%) and 5 surgeons (67 patients; 58.3%).
- Enrollment: RMCC, Denver CO - 48 pts, SCCA, Little Rock, AR - 28 pts, TCH, Cincinnati, OH - 15 pts, UCSF, San Francisco, CA - 9 pts, UMSJMC, Towson MD - 9 pts, SEH, Edgewood, KY - 6 pts

Table 1. Patient/Tumor Characteristics (N=115)

Characteristic	N (%)	Characteristic	N (%)	Characteristic	N (%)
<b>Patient Age</b>	Median 61 yr	<b>Distance from Margin (mm)</b>		<b>ER (IHC)<sup>a</sup></b>	
<50	18 (15.7)	Mean (SD)	4.2 (4.2)	Negative	8 (7.0)
50–59	38 (33.0)	Median (range)	3 (0–20)	Positive	99 (86.1)
60–69	41 (35.7)	Missing	2 (1.7)	<b>PR (IHC)<sup>a</sup></b>	
≥70	18 (15.7)	<1	11 (9.6)	Negative	16 (13.9)
<b>Postmenopausal</b>	86 (74.8)	1–1.9	27 (23.5)	Positive	91 (79.1)
<b>DCIS Size (mm)</b>		2–2.9	14 (12.2)	<b>ER (RT-PCR)</b>	
Mean (SD)	13.6 (15.7)	3–4.9	21 (18.3)	Negative	13 (11.3)
≤5	42 (36.5)	5–9.9	20 (17.4)	Positive	102 (88.7)
6–10	27 (23.5)	≥10	20 (17.4)	<b>PR (RT-PCR)</b>	
11–20	23 (20.0)	<b>Necrosis</b>		Negative	22 (19.1)
>20	23 (20.0)	Not identified	25 (21.7)	Positive	93 (80.9)
<b>Nuclear Grade</b>		Not reported	16 (13.9)		
I	23 (20.0)	Central	41 (35.7)		
II	53 (46.1)	Focal	33 (28.7)		
III	39 (33.9)				

<sup>a</sup>for N=1 (0.9%) result was uninterpretable; N=7 (6.1%) were missing.  
Race<sup>b</sup>: Caucasian - 77.4%, Black - 8.7%, Asian - 6.1%, Hispanic/Latino - 4.3% and Other/unknown - 7.8%  
<sup>b</sup>Pts could select more than one ethnicity (e.g. Caucasian and Asian)

Characteristic	Current Study N=110	E5194 N=327
<b>Age (years)</b>	Median (Range) 61 (36–83)	
<50	15.5%	20.2%
<b>DCIS Size (mm)</b>	Median (Range) 8 (1–115)	7
Low	20%	8.9%
<b>Nuclear Grade</b>	Intermediate 46.4%	57.2%
High	33.6%	33.9%
<b>Closest Margin (mm)</b>	Median (Range) 3 (0–20)	
<3	48.1%	3.0%
<b>Necrosis</b>	Present 63.6%	34.9%
<b>ER</b>	Positive 85.5%	97.2%

- The clinicopathologic variables observed in this study were comparable to the ECOG 5194 validation study, with exception of age (<50 years 15.5% vs 20.2%) and closest margin (<3 mm 48.1% vs 3%).

Figure 2. Range of Oncotype DX DCIS Score Results





Table 3. Pre- to Post-Assay Change in XRT Recommendations

	N	Percent	95% CI <sup>a</sup>	Change Rate
<b>Pre-assay XRT recommendation</b>	84	73.0%	64.0%–80.9%	–
<b>Change to Post-assay No XRT recommendation</b>	26	22.6%	15.3%–31.3%	<b>30.9%</b>
<b>Pre-assay No XRT recommendation</b>	31	27.0%	19.1%–36.0%	–
<b>Change to Post-assay XRT recommendation</b>	10	8.7%	4.2%–15.4%	<b>32.2%</b>
<b>Total patients with change in recommendation from pre-assay to post-assay</b>	36		23.0%–40.6%	<b>31.3%</b>

<sup>a</sup>Clopper-Pearson Exact confidence interval.

- 31.3%** (95% CI: 23.0–40.6%) of patients had a change in recommendation for XRT from pre- to post-assay:
  - 26 patients changed from a pre-score XRT recommendation to No-XRT post-score. 10 patients changed from pre-score No-XRT recommendation to XRT post-score.
  - All of the patients with a high DCIS Score result had a recommendation for XRT post assay.


Figure 3. Individual Patient 10-year LR Risk Assessments (Pre- and Post-DCIS Score result)



- Mean 10-year LR risk assessments decreased from pre-assay to post-assay:
  - Any LR from 21.1% (range: 6–60%) pre-assay to 18.2% (5–50%) post-assay
  - Invasive LR from 10.9% (range: 3–25%) pre-assay to 8.7% (2–25%) post-assay
- The average assessment of risk for any LR decreased in the low DCIS Score group (19.9% to 14.3%; p<0.001) and increased in the high result group (23.2% to 27.9%; p=0.057).
- The average assessment of risk for invasive LR decreased in the low result group (10.1% to 6.2; p<0.01) and increased in the high result group (13.1% to 15.2%; p=0.124).

## RESULTS (CONT.)

Figure 4. Changes in Recommendation for XRT Based on DCIS Score Result Group



- There was an associated shift in XRT recommendation in the high risk group towards XRT, consistent with the overall risk assessment.

Figure 5. Recommendations for XRT





Figure 6. Distribution of the DCIS Score Result by Clinical and Pathologic (CP) Factors

- There was a range of DCIS Score results across the CP characteristics within each group - e.g. age >70y, 50–70y and <50y.



## CONCLUSIONS

- The Oncotype DX Breast Cancer assay for DCIS is the first genomic test that provides an individualized assessment of the likelihood of local recurrence for patients diagnosed with DCIS and differentiates patients with a lower LR risk from those with higher risk.
- The DCIS Score result was clinically validated in a cohort of patients from the ECOG 5194 study and showed a strong and independent association with LR for any recurrence or an invasive recurrence.
- The results of the first clinical utility study demonstrate that:
  - Integration of the DCIS Score result changes treatment recommendations for XRT 31.3% of the time: pre-assay 73% of the patients had a recommendation for XRT vs 59% post-assay.
  - Mean pre-assay LR risk assessment based on traditional CP features alone was 21% vs 18% post assay and was indicative of the impact of the score result on risk estimates.
    - There was a decrease in risk assessment in patients with low score results and an increase in risk assessment in patients with high score results.
  - There was a range of DCIS Score results across the CP characteristics including age, grade, size and margin width, indicating that CP factors alone are insufficient to fully assess LR risk.
- Changes in recommendation were concentrated in patients with low and high DCIS score results:
  - 25 of 27 changes in patients with low scores eliminated previously recommended XRT.
  - 6 out of 6 changes in patients with high scores added XRT, where none had been previously recommended.
- These results support the clinical utility of the DCIS Score result as an important tool for assessing risk of LR in patients with DCIS after surgical excision.
  - The DCIS Score result reflects the individual patient's underlying tumor biology beyond the traditional CP factors.
  - The result provides a quantitative estimate of the risk of any LR (DCIS or invasive) or an invasive LR. Other estimates based on traditional CP factors can only provide group estimates of any LR and no specific information on the risk of an invasive LR.
- Better definition of underlying LR risk is critically important for improving treatment decisions, impacting overall patient outcomes, and addressing the issue of overtreatment with XRT in patients with DCIS.

## REFERENCES

- Stiegel et al. *CA Cancer J Clin.* 2014.
- Ernster et al. *J Natl Cancer Inst.* 2002.
- NCCN Guidelines<sup>™</sup>, Breast Cancer, v2.2014.
- Hughes et al. *J Clin Oncol.* 2009.
- Solin et al. *J Natl Cancer Inst.* 2013.

Oncotype DX, DCIS Score, and Genomic Health are registered trademarks of Genomic Health, Inc. NCCN and NCCN Guidelines are trademarks of the National Comprehensive Cancer Network. The guidelines do not endorse products or therapies. The authors thank Kevin Chew, Emily Burke, and Megan Robitney for their contributions.

## OBJECTIVES

### Primary

- To estimate the proportion of patients for whom obtaining the DCIS Score result lead to a change in the recommendation for XRT

### Exploratory

- To determine whether the proportion of patients for whom physicians recommended XRT changed from pre- to post-DCIS Score result

## METHODS

### Study Design

- Prospectively enrolled observational study of newly diagnosed patients with histologically proven pure DCIS
- Physicians filled out standardized questionnaires prior to and after the DCIS Score results were known
  - Pre-assay data collected: patient characteristics, pathology/ER/PR, treatment recommendations, physician estimate of LR risk
  - Post-assay data collected: DCIS Score result reported, treatment recommendation, physician estimate of LR risk, factors affecting physician recommendations
- Patient and tumor characteristics were abstracted from the medical record
- The study was approved by Institutional Review Boards at each study site

### Patient Population

- Each participating center was responsible for identifying eligible patients from among actively treated patients at the site using the following criteria:
  - Inclusion Criteria:** ≥18 years old, female, histologically proven DCIS, eligible for breast conserving therapy, surgical excision pathology report available, DCIS Score result ordered but result not yet available
  - Exclusion Criteria:** LCIS without DCIS, invasive carcinoma, mastectomy planned

### Data Collection

- Trained data coordinators at each site reviewed patient records and prospectively collected data using a secure electronic data capture form before (pre-assay) and after (post-assay) the DCIS Score results were known to the treating physician

### Statistical Considerations

- All analyses were descriptive unless otherwise specified
  - Clinical and pathological data are presented as mean (SD), median (range) for continuous variables and N (%) for categorical data
  - Results are presented for all patients and within pre-defined DCIS Score result risk groups: Low <39, Intermediate 39–54, High ≥ 55
- Hypothesis testing was performed using SAS<sup>®</sup> version 9.2 (SAS Institute, Cary, NC)
  - McNemar's test was used to determine if a significant proportion of patients had a change in XRT recommendation after receiving the DCIS Score result
  - P< 0.05 was considered significant

### Limitations

- Physicians in this study were early adopters of the assay